HC Wainwright reissued their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a report published on Monday, Benzinga reports. They currently have a $6.00 price objective on the stock.
A number of other analysts also recently weighed in on the company. Brookline Capital Management assumed coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They set a buy rating and a $8.00 target price for the company. Chardan Capital reissued a buy rating and set a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday.
Check Out Our Latest Stock Report on SABS
SAB Biotherapeutics Stock Down 3.9 %
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.34. The firm had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative return on equity of 109.90% and a negative net margin of 1,531.26%. Equities analysts anticipate that SAB Biotherapeutics will post -4.08 earnings per share for the current fiscal year.
Hedge Funds Weigh In On SAB Biotherapeutics
Institutional investors have recently modified their holdings of the business. RTW Investments LP acquired a new position in SAB Biotherapeutics in the 4th quarter worth about $6,310,000. BVF Inc. IL acquired a new position in SAB Biotherapeutics in the 4th quarter worth about $6,310,000. Commodore Capital LP acquired a new position in SAB Biotherapeutics in the 4th quarter worth about $1,259,000. Finally, First PREMIER Bank acquired a new position in SAB Biotherapeutics in the 2nd quarter worth about $60,000. Institutional investors and hedge funds own 7.82% of the company’s stock.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
See Also
- Five stocks we like better than SAB Biotherapeutics
- 5 discounted opportunities for dividend growth investors
- Brinker International’s Price Dip is an Appetizing Entry Point
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Stocks That Could Beat the September Blues
- Dividend Capture Strategy: What You Need to Know
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.